Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review

被引:25
作者
Couteau, Nicolas [1 ]
Duquesne, Igor [2 ]
Frederic, Panthier [1 ]
Thiounn, Nicolas [1 ]
Timsit, Marc-Olivier [1 ]
Mejean, Arnaud [1 ]
Pinar, Ugo [3 ]
Audenet, Francois [1 ]
机构
[1] Univ Paris, Serv Urol, Hop Europeen Georges Pompidou, F-75015 Paris, France
[2] Univ Paris, Serv Urol, Hop Cochin, F-75014 Paris, France
[3] Sorbonne Univ, Serv Urol, Hop La Pitie Salpetriere, F-75013 Paris, France
关键词
benign prostatic hyperplasia; ejaculation; endoscopic enucleation; anatomy; ejaculation disorders; URINARY-TRACT SYMPTOMS; HOLMIUM LASER ENUCLEATION; TRANSURETHRAL RESECTION; SEXUAL FUNCTION; RANDOMIZED-TRIAL; SINGLE-CENTER; DOUBLE-BLIND; EFFICACY; MEN; SAFETY;
D O I
10.3390/jcm10245788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Benign prostatic hyperplasia (BPH) is commonly responsible for lower urinary tract symptoms (LUTS) in men aged 50 or over. Sexual dysfunctions, such as ejaculatory disorders (EjD), go along with LUTS but are frequently overlooked in the initial evaluation. This review aimed to detail BPH-related EjD, as well as their modifications by medical, surgical, and interventional treatments. Methods: We conducted a narrative review looking for publications between 1990 and 2020, regarding physiopathology, epidemiology, evaluation, and therapeutic management (medical, surgical, and interventional) of BPH-related EjD. Results: Sixty-five articles were included in our final analysis. Forty-six percent of men presenting with LUTS reported EjD. If the prevalence increases with age and LUTS severity, the functional impairment is not correlated with age. Several self-questionnaires evaluated the sexual function, but only four approaches are specific to EjD. Medical therapies were exposed to anejaculation, rather than retrograde ejaculation (RE) (4-30% (alpha-blockers), 4-18% (5-alpha-reductase inhibitors)). Regarding surgical therapies, trans-urethral resection of the prostate (TURP) and incision of the prostate (TUIP) are associated with 50-70% and 21-35% of RE. The RE rate is important after open simple prostatectomy but can be reduced with robotic approaches and urethral sparing techniques (19%). Anatomic endoscopic enucleation of the prostate (AEEP) with or without a laser source is associated with an 11-36% RE rate, according to supramontanal preservation. Recent surgical techniques (Rezum (c), Aquablation (c), or Urolift (c)) were developed to preserve antegrade ejaculation with promising short-term results. Regardless of the surgical approach, anatomic studies suggest that the preservation of peri-montanal tissue (7.5 mm laterally; 10 mm proximally) is primordial to avoid post-operative RE. Finally, prostate artery embolization (PAE) limits the RE rate but exposes it to a 12 months 10% re-intervention rate. Conclusion: EjD concerns almost half of the patients presenting BPH-related LUTS. Initial evaluation of EjD impairment is primordial before medical or surgical therapy. Peri-montanal tissue preservation represents a key point for antegrade ejaculation preservation, regardless of the surgical option.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review
    Madersbacher, Stephan
    Sampson, Natalie
    Culig, Zoran
    [J]. GERONTOLOGY, 2019, 65 (05) : 458 - 464
  • [42] Conservative non-instrumental treatment of benign prostatic hyperplasia
    Bosch, JLHR
    [J]. UROLOGICAL RESEARCH, 1997, 25 : S107 - S114
  • [43] Orthostatic Hypotension in Benign Prostatic Hyperplasia Patients and Its Association With Alpha-1 Antagonist Use: A Comprehensive Literature Review
    Abubakar, Muhammad
    Prasad, Rachna
    Salim, Siffat S.
    Basavaraju, Deepak
    Khan, Munazza
    Lateef, Ibrahim K.
    Furqan, Ahmad
    Raza, Saud
    Gupta, Ishita
    Singla, Deepak
    Adil, Hira
    Naeem, Ather
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [44] Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review
    Tsunemori, Hiroyuki
    Sugimoto, Mikio
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (11) : 1086 - 1092
  • [45] Benign prostatic hyperplasia New and treatment-relevant aspects from the DGU guidelines
    Bach, T.
    Heitz, M.
    Bruns, T.
    [J]. UROLOGE, 2020, 59 (05): : 544 - 549
  • [46] Epidemiology of benign prostatic hyperplasia
    Robert, G.
    De La Taille, A.
    Descazeaud, A.
    [J]. PROGRES EN UROLOGIE, 2018, 28 (15): : 803 - 812
  • [47] Medical Advancements in Benign Prostatic Hyperplasia Treatments
    Ganesan, Vishnuvardhan
    Agarwal, Deepak
    [J]. CURRENT UROLOGY REPORTS, 2024, 25 (05) : 93 - 98
  • [48] Treatment of benign prostatic hyperplasia: Update and future
    Chiu, Tai-Hua
    Wu, Yi-Hsuan
    Lee, Yung-Chin
    [J]. UROLOGICAL SCIENCE, 2023, 34 (02) : 55 - 63
  • [49] Drugs for Benign Prostatic Hyperplasia
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1649): : 65 - 69
  • [50] Is there a best timing for benign prostatic hyperplasia surgery?
    Fourmarier, Marc
    Baboudjian, Michael
    Robert, Gregoire
    Lebdai, Souhil
    [J]. FRENCH JOURNAL OF UROLOGY, 2024, 34 (02):